Predictors and trajectory of performance status in patients with advanced cancer: A secondary data analysis of the international European Palliative Care Cancer Symptom study

Boland, Jason

http://hdl.handle.net/10026.1/17474

10.1177/0269216318811011
Palliative Medicine
SAGE Publications

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Predictors and trajectory of performance status in patients with advanced cancer: A secondary data analysis of the international European Palliative Care Cancer Symptom study

Jason W Boland¹, Victoria Allgar², Elaine G Boland³, Stein Kaasa⁴, Marianne J Hjermstad⁴ and Miriam J. Johnson¹

Abstract

Background: Performance status, a predictor of cancer survival, and ability to maintain independent living deteriorate in advanced disease. Understanding predictors of performance status trajectory could help identify those at risk of functional deterioration, target support for independent living and reduce service costs. The relationship between symptoms, analgesics and performance status is poorly delineated.

Aim: The aim of this study is to determine whether demographics, analgesics, disease characteristics, quality-of-life domains and C-reactive protein predict the trajectory of Karnofsky Performance Status (KPS) in patients with advanced cancer.

Design: The study design is the secondary data analysis of the international prospective, longitudinal European Palliative Care Cancer Symptom study (ClinicalTrials.gov: NCT01362816). A multivariable regression model was built for KPS area under the curve per day (AUC).

Setting and participants: This included adults with advanced, incurable cancer receiving palliative care, without severe cognitive impairment and who were not imminently dying (n = 1739).

Results: The mean daily KPS AUC (n = 1052) was 41.1 (standard deviation = 14.1). Opioids (p < 0.001), co-analgesics (p = 0.023), poorer physical functioning (p < 0.001) and appetite loss (p = 0.009) at baseline were explanatory factors for lower KPS AUC. A subgroup analysis of participants with C-reactive protein data (n = 240) showed that only C-reactive protein (p = 0.040) and physical function (p < 0.001) were associated with lower KPS AUC.

Conclusion: This study is novel in determining explanatory factors for subsequent functional trajectories in an international dataset and identifying systemic inflammation as a candidate therapeutic target to improve functional performance. The effect of interventions targeting physical function, appetite and inflammation, such as those used for cachexia management, on maintaining functional status in patients with advanced cancer needs to be investigated.

Keywords

Karnofsky Performance Status, appetite, inflammation, neoplasms, opioids, analgesics

What is already known about the topic?

- Performance status and ability to maintain independent living deteriorate in advanced disease and are associated with cancer survival.
- Palliative care interventions may help support independent living and reduce health and social care costs.
- The relationships between symptoms, analgesics and performance status are poorly delineated.

¹Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK
²Hull York Medical School, University of York, York, UK
³Hull and East Yorkshire Hospitals NHS Trust, Hull, UK
⁴European Palliative Care Research Centre (PRC), Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Corresponding author:
Jason W Boland, Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.
Email: Jason.Boland@hyms.ac.uk
What this paper adds?

- Opioids, co-analgesics, poorer physical functioning and appetite loss at baseline were associated with a lower Karnofsky Performance Status over time.
- In a subgroup analysis which included C-reactive protein, only this and physical function were associated with a lower Karnofsky Performance Status over time.
- This study identifies systemic inflammation as a candidate therapeutic target to improve functional performance.

Implications for practice, theory or policy

- A thorough assessment of clinical and patient-reported data is needed to identify and subsequently manage issues potentially leading to a deteriorating performance status.
- The effect of interventions to improve physical function, appetite and inflammation, such as those used for cachexia management, on maintaining functional status in patients with advanced cancer needs to be investigated.
- Further research assessing this association and the impact of managing systemic inflammation on clinical outcomes is needed.

Introduction

Performance status is an independent predictor of cancer survival.\textsuperscript{1–5} It is often impaired in patients with advanced disease.\textsuperscript{4} Performing activities of daily living is an important patient priority; minimising burden on others was ‘very important’ for 89% patients.\textsuperscript{6} Symptoms negatively impact function.\textsuperscript{7,8} Pain is associated with decreased Karnofsky Performance Status (KPS).\textsuperscript{9} Better symptom management could improve performance status. However, longitudinal data exploring the association between symptoms, analgesics and performance status are limited. Understanding predictors of performance status could help identify those at risk of deterioration, so palliative interventions can be planned.\textsuperscript{10,11} If such interventions help maintain function sufficient for independent community-based living, health and social care costs could be reduced.\textsuperscript{12} KPS is a measure of overall function (including impact of psychosocial factors), allowing patients to be classified according to their functional impairment.\textsuperscript{13} C-reactive protein (CRP), as a marker of inflammation, has been associated with poorer performance.\textsuperscript{14}

Aim

The aim of this study is to explore whether demographics, analgesics, disease characteristics and the palliative care version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Core15 (EORTC QLQ-C15-PAL) items at baseline predict KPS trajectory in patients with advanced cancer and the effect of CRP on these relationships. Our null hypothesis is that there is no relationship between these variables and performance status over time.

Methods

Study design

The study design is the secondary data analysis of the prospective, longitudinal, multi-site European Palliative Care Cancer Symptom study (ClinicalTrials.gov: NCT01362816), which recruited from April 2011 to October 2013.\textsuperscript{15} Detailed study methods have been published.\textsuperscript{15} Eligible participants were consenting adults (≥18 years) with advanced, incurable cancer receiving palliative care, not imminently dying and scoring ≥4/8 on the four-item Mini–Mental State Examination. Data registration consisted of registration of patients’ medical data by healthcare providers, and patient self-reported data on key sociodemographic items: age, sex and living situation and questions about common cancer-related symptoms, quality of life and functional status. Assessments were performed upon study inclusion and monthly ±1-week follow-up, either at hospital or by mailed postal questionnaires, for at least 6 months if possible.\textsuperscript{15}

In total, the dataset included 1739 patients. The baseline characteristics have been published previously.\textsuperscript{15} This analysis uses the full dataset, and records with occasional missing values for single variables were retained. Table 1 shows data collected at each visit.

Statistical analyses

The characteristics of the patients are presented for the baseline assessment using mean and standard deviation (SD), minimum and maximum, or n (%).

The dependent outcome measure was area under the curve (AUC) for performance status using KPS. All serial measurements of KPS were plotted against time. AUC from entry to the study to death (KPS of zero assigned) was calculated using the trapezoid rule.\textsuperscript{17} The summary score for KPS was expressed as the total area under the KPS curve from study entry until death, divided by the total number of days represented (KPS AUC per day), thereby reflecting average but not actual daily scores.

To compare mean KPS AUC per day and categorical variables (sex, location, cancer stage and analgesics), two-tailed Student’s t-tests or analysis of variance (ANOVA) tests were used. Pearson’s correlations were used for age and the EORTC QLQ-C15-PAL scales and items. Candidate
Table 1. Data collected at each assessment visit.

| Collected by healthcare providers | Self-reported patient measures |
|----------------------------------|-------------------------------|
| • Patient location: inpatient, day care/outpatient, home | The palliative care version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–15 (EORTC QLQ-C15-PAL).\textsuperscript{16} Item scored from 1 'not at all' to 4 'very much' and was transformed to a 0–100 scale |
| • Karnofsky Performance Status (KPS): 0%–100%; 100 is 'perfect' health and 0 is dead | • Functional items: high score means a good function or quality of life |
| • Analgesic use (yes/no), for non-opioid analgesics, opioids and co-analgesics | o Physical functioning |
| o Co-analgesics were defined as drugs that are not designed to manage pain per se, but which has effects that can help reduce the pain, for example, antidepressants and anticonvulsants | o Emotional functioning |
| o Non-opioid analgesics included paracetamol and non-steroidal anti-inflammatory drugs. | o Global quality of life |
| • C-reactive protein (CRP) | • Symptom items: high score indicates more severe symptoms |

Ethical approval

Ethical approval was obtained at each European Palliative Care Cancer Symptom study recruiting site. The Regional Research Ethics Committee in Medicine, Central Norway, evaluated and accepted the project on 26 November 2010. The study was performed according to the Declaration of Helsinki. No further ethical approval was necessary for this secondary analysis of anonymised data (http://www.hra.nhs.uk).

Results

Patient characteristics

At baseline, 1739 patients were included (65.8 years (SD = 12.4 years), range = 21–97 years; men 50%). Baseline characteristics are shown in Table 2. At baseline, the mean KPS score was available for 1724 patients. The mean KPS score at baseline was 67.0 (16.5), and 719 (42%) had a performance status <70%. The last recorded KPS values showed a mean KPS of 62.8 (18.2) and 895/1730 (52%) had performance status below 70%.

During the study, 1090 patients died (25 with no documented date of death). The characteristics of these patients are shown in Table 2. AUC was calculated for 1052 patients, where baseline KPS was recorded. The mean KPS AUC per day was 41.1 (14.1) and data were normally distributed. Mean KPS AUC per day was lower for those with baseline KPS <70% (33.3 (11.9)) than those scoring ≥70% (49.0 (11.6), p < 0.001). Similarly, mean KPS AUC per day at their last study visit was lower for those with KPS <70% (36.5 (13.0)) than those scoring ≥70% (49.0 (12.3), p < 0.001).

Table 3 shows a univariable analysis of baseline characteristics and mean (SD) KPS AUC per day. Increasing age was associated with lower KPS AUC per day (r = −0.153, p < 0.01). The mean KPS AUC per day was lower for those who were an inpatient and used any opioid, non-opioid analgesic and co-analgesic at baseline. However, higher mean KPS AUC per day was seen in those with metastatic/disseminated disease at baseline compared to local/locally advanced.

Table 4 shows the correlations between EORTC QLQ-C15-PAL items and KPS AUC per day; the strongest correlation was for physical functioning (r = 0.539). Except nausea/vomiting, more severe symptoms were correlated with lower KPS AUC per day.

Table 5 shows the univariable and multivariable analyses. Older age (p = 0.004), opioids (p < 0.001), co-analgesics (p = 0.023), lower levels of physical functioning (p < 0.001) and more severe appetite loss (p = 0.009) at baseline remained as independent explanatory factors for reduced KPS AUC over time. Together these factors explained 34.8% (R\textsuperscript{2} of final model) of the relationship, indicating that other variables are important.
In the subgroup analysis, the baseline characteristics of participants with CRP data (n = 240) are shown in Table 2. These patients were slightly older and there was a higher proportion male, with metastatic/disseminated disease, inpatient and lower KPS, compared to the whole sample. Only CRP and physical function were associated with change in KPS: lower physical functioning ($\beta$ (SE) = −0.09 (0.32), $p = 0.004$); opioids use ($\beta$ (SE) = −3.63 (0.89), $p < 0.001$); co-analgesics use ($\beta$ (SE) = −2.04 (0.90), $p = 0.023$); poorer physical function, where a high score means a good physiological function ($\beta$ (SE) = 0.19 (0.03), $p < 0.001$); and appetite loss at baseline, where a high score indicates more severe symptoms ($\beta$ (SE) = −0.03 (0.01), $p = 0.009$) were independent predictors of worse KPS over time in patients with advanced cancer. A CRP subgroup analysis showed

| Table 2. Descriptive characteristics at baseline. |
|--------------------------------------------------|
| Total Mean (SD), min–max, n (%) | Patients with CRP at baseline Mean (SD), min–max, n (%) | Patients who died Mean (SD), min–max, n (%) |
|----------------------------------|--------------------------------------------------|----------------------------------|
| **Age (years)** | 65.8 (12.4), 21–97 $n = 1739$ | 67.3 (12.1) $n = 240$ | 66.6 (12.5), 23–97 $n = 1052$ |
| **Sex** | | | |
| Female | 871 (50%) | 101 (42%) | 478 (45%) |
| Male | 866 (50%) | 139 (58%) | 574 (55%) |
| Missing | 2 | 0 | 0 |
| **Stage** | | | |
| Metastatic/disseminated | 1437 (84%) | 219 (91%) | 887 (84%) |
| Local/locally advanced | 284 (16%) | 21 (9%) | 163 (16%) |
| Missing | 48 | 0 | 28 |
| **Location of care** | | | |
| Inpatient | 365 (21%) | 105 (44%) | 275 (27%) |
| Day care | 1026 (61%) | 92 (38%) | 595 (58%) |
| Home | 300 (18%) | 36 (15%) | 154 (15%) |
| Missing | 18 | 7 | 2 |
| **Non-opioid analgesics** | | | |
| Yes | 808 (47%) | 103 (43%) | 552 (53%) |
| No | 896 (53%) | 134 (57%) | 486 (47%) |
| Missing | 35 | 3 | 14 |
| **Opioids** | | | |
| Yes | 1012 (59%) | 136 (58%) | 677 (65%) |
| No | 694 (41%) | 99 (42%) | 361 (35%) |
| Missing | 33 | 5 | 14 |
| **Co-analgesics** | | | |
| Yes | 410 (24%) | 41 (17%) | 257 (25%) |
| No | 1279 (76%) | 194 (83%) | 768 (75%) |
| Missing | 50 | 5 | 27 |
| **CRP** | 55.0 (77.7), 0–379, n = 240 | 55.0 (77.7), 0–379, n = 240 | 65.8 (77.9), 1–379, n = 185 |
| **KPS** | 67.0 (16.5), 10–100, n = 1724 | 63.9 (18.7), 20–100, n = 239 | 63.8 (16.2), 10–100, n = 1052 |
| **EORTC QLQ-C15-PAL** | | | |
| Physical functioning | 64.8 (29.2), 0–100, n = 1698 | 56.1 (30.5), 0–100, n = 232 | 59.7 (29.6), 0–100, n = 1021 |
| Emotional functioning | 68.7 (23.9), 0–100, n = 1695 | 70.3 (26.2), 0–100, n = 232 | 69.5 (24.0), 0–100, n = 1019 |
| Global quality of life | 51.5 (26.3), 0–100, n = 1682 | 48.4 (27.2), 0–100, n = 229 | 49.5 (26.1), 0–100, n = 1009 |
| Fatigue | 50.0 (28.7), 0–100, n = 1700 | 53.6 (31.4), 0–100, n = 232 | 52.2 (28.6), 0–100, n = 1022 |
| Nausea/vomiting | 17.4 (27.4), 0–100, n = 1699 | 21.3 (29.6), 0–100, n = 222 | 18.6 (28.0), 0–100, n = 1012 |
| Pain | 38.3 (31.1), 0–100, n = 1700 | 43.6 (34.2), 0–100, n = 232 | 40.9 (31.5), 0–100, n = 1022 |
| Dyspnoea | 23.3 (28.9), 0–100, n = 1694 | 28.1 (31.0), 0–100, n = 231 | 26.7 (30.8), 0–100, n = 1018 |
| Sleep disturbances | 31.3 (28.9), 0–100, n = 1693 | 34.2 (33.8), 0–100, n = 231 | 30.8 (32.3), 0–100, n = 1019 |
| Appetite loss | 33.8 (34.8), 0–100, n = 1698 | 42.0 (37.3), 0–100, n = 232 | 36.8 (35.3), 0–100, n = 1021 |
| Constipation | 27.5 (31.8), 0–100, n = 1688 | 32.5 (34.7), 0–100, n = 228 | 30.0 (33.3), 0–100, n = 1012 |

*SD: standard deviation; CRP: C-reactive protein; KPS: Karnofsky Performance Status; EORTC QLQ-C15-PAL: The Palliative Care version of the EORTC Quality of Life Questionnaire.*

**CRP subgroup analysis**

In the subgroup analysis, the baseline characteristics of participants with CRP data (n = 240) are shown in Table 2. These patients were slightly older and there was a higher proportion male, with metastatic/disseminated disease, inpatient and lower KPS, compared to the whole sample. Only CRP and physical function were associated with change in KPS: lower physical functioning ($\beta$ (SE) = 0.15 (0.04), $p < 0.001$) and CRP ($\beta$ (SE) = −0.03 (0.01), $p = 0.040$). Opioids ($p = 0.114$), co-analgesics ($p = 0.187$) and severe appetite loss ($p = 0.078$) were not significant. The $R^2$ value of this model was 34.0%.

**Discussion**

**Summary of main findings**

These data indicate that older age ($\beta$ (SE) = −0.09 (0.32), $p = 0.004$); opioids use ($\beta$ (SE) = −3.63 (0.89), $p < 0.001$); co-analgesics use ($\beta$ (SE) = −2.04 (0.90), $p = 0.023$); poorer physical function, where a high score means a good physiological function ($\beta$ (SE) = 0.19 (0.03), $p < 0.001$); and appetite loss at baseline, where a high score indicates more severe symptoms ($\beta$ (SE) = −0.03 (0.01), $p = 0.009$) were independent predictors of worse KPS over time in patients with advanced cancer. A CRP subgroup analysis showed
that this inflammatory marker was statistically significant at explaining worse performance. In this model, only CRP and physical function remained significantly associated with deteriorating KPS. In both models, two-thirds of the variability was unexplained. KPS incorporates a much broader construct than physical function alone, also consisting of mental and behavioural approaches and social support.

The only statistically significant symptom remaining in the final model in the whole dataset was loss of appetite. This is consistent with the findings of the CRP sub-analysis. In a Japanese secondary data analysis, increased CRP was associated with more physician-rated symptoms (fatigue, anorexia and weight loss dyspnoea) and poorer activities of daily living were observed in advanced cancer patients receiving palliative care. Although this study primarily looked for associations with KPS, there are similarities in the findings, notably the association of CRP with cancer-cachexia symptoms and ability to perform everyday tasks. Inflammation could act as a uniting pathophysiological process for analgesics, poorer physical function and loss of appetite. Inflammatory cancers are more painful. Inflammatory cytokines mediate cancer cachexia with accompanying anorexia and loss of skeletal muscle mass with reduction in physical function and worse prognosis. Inflammation leading to fatigue decreases exercise capacity and movement, exacerbating skeletal muscle loss. There is a need to detect cancer-related cachexia early, and have a multimodal approach, to maintain function for as long as possible.

**Implications for practice**

This study was an exploratory analysis to indicate patients at risk of deterioration in performance status, and targets for intervention to ameliorate this decline. These data suggest that attention to the inflammatory state with accompanying anorexia cachexia, including regular weight measurement and appetite assessment and nutritional status, is important in this context.

**Limitations**

This was a large European prospective cohort study; as it was an observational study, only associations (not causation) can be determined. Although consecutive patients were recruited, those with cognitive impairment were excluded. Some of the statistical associations had small effect sizes and are unlikely to be clinically relevant, as reported in a previous study. Pro-inflammatory cytokines, acute infections and acute medical conditions influence CRP levels. The associations found in the subgroup analysis need to be examined in a larger group.

---

**Table 3.** Karnofsky Performance Status area under the curve per day by baseline characteristics.

| Baseline characteristics | Mean (SD) | N   | p-Value |
|---------------------------|-----------|-----|---------|
| Sex                       |           |     |         |
| Female                    | 41.4 (13.6) | 478 | 0.434   |
| Male                      | 40.8 (14.6) | 574 |         |
| Stage                     |           |     |         |
| Local/locally advanced    | 38.9 (13.1) | 163 | 0.036   |
| Metastatic/disseminated   | 41.5 (14.3) | 887 |         |
| Location of care          |           |     |         |
| Inpatient                 | 33.4 (12.9) | 275 | <0.001  |
| Day care                  | 46.0 (12.4) | 595 |         |
| Home                      | 35.9 (14.6) | 154 |         |
| Non-opioid analgesics     |           |     |         |
| Yes                       | 41.1 (13.5) | 552 | 0.045   |
| No                        | 41.3 (14.8) | 486 |         |
| Opioids                   |           |     |         |
| Yes                       | 38.9 (13.4) | 677 | <0.001  |
| No                        | 45.4 (14.6) | 361 |         |
| Co-analgesics             |           |     |         |
| Yes                       | 39.1 (12.9) | 257 | 0.004   |
| No                        | 42.0 (14.5) | 768 |         |

SD: standard deviation. The total number of participants included for each characteristic is variable due to missing data. p-Values that reached statistical significance are in bold.

**Table 4.** Correlations between EORTC QLQ-C15-PAL items and Karnofsky Performance Status area under the curve per day.

| EORTC QLQ-C15-PAL | Correlation | N    | p-Value |
|--------------------|-------------|------|---------|
| Physical functioning| 0.539       | 1021 | <0.001  |
| Emotional functioning| 0.216     | 1019 | <0.001  |
| Global quality of life | 0.242   | 1009 | <0.001  |
| Fatigue            | −0.315      | 1022 | <0.001  |
| Nausea/vomiting    | −0.031      | 1021 | 0.326   |
| Pain               | −0.209      | 1022 | <0.001  |
| Dyspnoea           | −0.151      | 1018 | <0.001  |
| Sleep disturbances | −0.076      | 1019 | 0.015   |
| Appetite loss      | −0.255      | 1021 | <0.001  |
| Constipation       | −0.177      | 1012 | <0.001  |

EORTC QLQ-C15-PAL: The Palliative Care version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire. p-Values that reached significance are in bold.
Conclusion

This secondary data analysis of the European Palliative Care Cancer Symptom study data set of adults with advanced, incurable cancer showed an association of lower average daily KPS with opioids, co-analgesics, lower levels of physical functioning at baseline and appetite loss. A CRP sub-analysis indicated that systemic inflammation has a role in performance status and may be a useful therapeutic target to help patients maintain function. Interventions targeting physical function, appetite and inflammation, such as those used for cachexia management, may help maintain KPS in people with advanced cancer. Further research assessing this association and the impact of managing systemic inflammation on clinical outcomes is needed.

Acknowledgements

The European Palliative Care Cancer Symptom study (EPCCS) is a collaborative effort between the European Palliative Care Research Centre (PRC) and the European Association for Palliative Care – Research Network (EAPC-RN). EPCCS was partially funded by grant no. 6070 from the joint Research Council at Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital – Trondheim University Hospital.

Project management: Marianne J. Hjermstad, PRC/NTNU; Stein Kaasa, PRC/NTNU/EAPC-RN; Dagny F. Haugen, PRC/NTNU; Pål Klepstad, PRC/NTNU; Gunnhild Jakobsen, PRC/NTNU, Norway; Augusto Caraceni, PRC/EAPC-RN; Cinzia Brunelli, PRC, Italy; Per Sjøgren, EAPC-RN, Denmark; Florian Strasser, Switzerland; Barry Laird, PRC, UK.

Project steering committee: Marianne J. Hjermstad, PRC/NTNU; Stein Kaasa, PRC/NTNU/EAPC-RN, Norway; Augusto Caraceni, PRC/EAPC-RN; Cinzia Brunelli, PRC, Italy; Per Sjøgren, EAPC-RN, Denmark; Luc Deliens, EAPC-RN, Belgium; Mike Bennett, EAPC-RN, UK; David Currrow, Australia; Vickie Baracos, Canada.

Core centre collaborators, one from each site: Erik Løhre, St. Olavs Hospital – Trondheim University Hospital; Nina Aass, Oslo University Hospital; Elisabeth Brenne, Øya Helsehus; Inge Raknes, Haraldsplass Deaconess Hospital, Norway; Geana Kurita, Rigshospitalet; Mogens Groenvold, Bispebjerg Hospital, Denmark; Florian Strasser, Cantonal Hospital St. Gallen; Cristian Camartin, Kantonsspital, Graubünden, Switzerland; Alessandra Pigni, Fondazione IRCCS Istituto Nazionale dei Tumori; Luigi Cavanna, Oncologia Medica Ospedale Di Piacenza; Adriana Turriziani, Hospice Villa Speranza Roma; Franco Rizzi, U.O. Complessa di Cure Palliative e Terapia del Dolo, AO ICP Milan; Laura Piva, Unità di Cure Palliative Azienda Ospedaliera San Paolo, Milan; Giampiero Porzio, Oncologia Medica Università degli Studi, L’Aquila; Rondini Ermanno, U.O. Oncologia Medica Arcispedale S. Maria Nuova – IRCCS, Reggio Emilia, Italy; Mike Bennett, Leeds Institute of Health Sciences, University of Leeds; Barry Laird, Western General Hospital Edinburgh, Beatson West of Scotland.

Table 5. Regression for Karnofsky Performance Status area under the curve per day.

|                      | Univariable |                      | Multivariable |                      |
|----------------------|-------------|----------------------|---------------|----------------------|
|                      | β (SE)      | p-Value              | β (SE)        | p-Value              |
| **Age**              | -0.17 (0.03)| <0.001               | -0.09 (0.32)  | 0.004                |
| **Sex (female)**     | 0.69 (0.87) | 0.434                | 0.64 (0.75)   | 0.393                |
| **Stage (local/locally advanced)** | -2.52 (1.2) | 0.036                | -1.17 (1.04)  | 0.260                |
| **Location of care** |             |                      |               |                      |
| Inpatient            | -2.51 (0.30)| 0.053                | 1.02 (1.23)   | 0.409                |
| Day care             | 10.07 (1.16)| <0.001               | 5.10 (1.14)   | <0.001               |
| Home                 |             |                      |               |                      |
| **Non-opioid (yes)** | -0.19 (0.88)| 0.832                | 1.03 (0.76)   | 0.180                |
| **Opioid (yes)**     | -6.48 (0.90)| <0.001               | -3.63 (0.89)  | <0.001               |
| **Co-analgesic (yes)** | -2.89 (1.01)| 0.004                | -2.04 (0.90)  | 0.23                 |
| **EORTC QLQ-C15-PAL**|         |                      |               |                      |
| Physical functioning  | 0.25 (0.01)| <0.001               | 0.19 (0.03)   | <0.001               |
| Emotional functioning | 0.13 (0.02)| <0.001               | 0.01 (0.02)   | 0.906                |
| Global quality of life| 0.13 (0.02)| <0.001               | 0.01 (0.02)   | 0.434                |
| Fatigue              | -0.15 (0.01)| <0.001               | -0.01 (0.02)  | 0.428                |
| Nausea/vomiting      | -0.02 (0.02)| 0.326                |               |                      |
| Pain                 | -0.10 (0.01)| <0.001               | 0.01 (0.02)   | 0.951                |
| Dyspnoea             | -0.07 (0.01)| <0.001               | -0.01 (0.01)  | 0.870                |
| Sleep disturbances   | -0.03 (0.01)| 0.015                | 0.02 (0.01)   | 0.170                |
| Appetite loss        | -0.10 (0.01)| <0.001               | -0.03 (0.01)  | 0.009                |
| Constipation         | -0.07 (0.01)| <0.001               | -0.01 (0.01)  | 0.724                |

SE: standard error; EORTC QLQ-C15-PAL: The Palliative Care version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire.

p-Values that reached statistical significance in the multivariable analysis are in bold.
Cancer Centre, Edinburgh; Andrew Wilcock, Nottingham University Hospitals NHS Trust, Nottingham; Karen Harvie, Marie Curie Hospice, Glasgow, UK; Maria Nabal, Hospital Universitário Arnau de Vilanova Lleida; Antonio N. Tejedor, Hospital Centro de Cuidados Laguna, Madrid; Josep Porta Sales, Institut Català d’Oncologia, Barcelona; Marina Martínez, Clínica Universidad De Navarra Pamplona, Spain; Konrad Fassbender, University of Alberta, Canada; David Currow, Flinders University, Australia; Nikolay Yordanov, Comprehensive Cancer Center Vratsa, Bulgaria; Koen Pardon, Ghent University Hospital Flanders, Belgium; Ioseb Abesadze, Cancer Prevention Center, Tbilisi, Georgia; Madalena Feio, Instituto Português de Oncologia Francisco Gentil Lisbon, Portugal. Data from the study are deposited at the Unit for Applied Clinical Research, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (https://www.ntnu.edu/mh/akf).

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was supported by the Central Norway Regional Health Authority (grant no. 46055100), The Cancer Foundation St Olavs Hospital, Trondheim University Hospital (grant no. 6070) and an unrestricted grant from the Helsinn Group, Switzerland.

ORCID iDs
Jason W Boland https://orcid.org/0000-0001-5272-3057
Victoria Allgar https://orcid.org/0000-0002-5228-2623
Miriam Johnson https://orcid.org/0000-0001-6204-9158

References
1. Yamada T, Morita T, Maeda I, et al. A prospective, multicenter cohort study to validate a simple performance status-based survival prediction system for oncologists. *Cancer* 2016; 123: 1442–1452.
2. Verweij NM, Schiphorst AH, Pronk A, et al. Physical performance measures for predicting outcome in cancer patients: a systematic review. *Acta Oncol* 2016; 55: 1386–1391.
3. Ferrat E, Paillaud E, Laurent M, et al. Predictors of 1-year mortality in a prospective cohort of elderly patients with cancer. *J Gerontol A Biol Sci Med Sci* 2015; 70: 1148–1155.
4. Laird BJ, Kaasa S, McMillan DC, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammatory-based prognostic system. *Clin Cancer Res* 2013; 19: 5456–5464.
5. Jang RW, Carasics VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status. *J Oncol Pract* 2014; 10: e335–e341.
6. Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. *JAMA* 2000; 284: 2476–2482.
7. Spoozak L, Seow H, Liu Y, et al. Performance status and symptom scores of women with gynecologic cancer at the end of life. *Int J Gynecol Cancer* 2013; 23: 971–978.
8. Sutrathdar R, Atzema C, Seow H, et al. Is performance status associated with symptom scores? A population-based longitudinal study among cancer outpatients. *J Palliat Care* 2014; 30: 99–107.
9. Smyth EN, Shen W, Bowman L, et al. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. *Health Qual Life Outcomes* 2016; 14: 52.
10. Downing M, Lau F, Lesperance M, et al. Meta-analysis of survival prediction with Palliative Performance Scale. *J Palliat Care* 2007; 23: 245–252; discussion 252–254.
11. Lau F, Downing M, Lesperance M, et al. Using the Palliative Performance Scale to provide meaningful survival estimates. *J Pain Symptom Manage* 2009; 38: 134–144.
12. Abernethy AP, Currow DC, Shelby-James T, et al. Delivery strategies to optimize resource utilization and performance status for patients with advanced life-limiting illness: results from the ‘palliative care trial’ [ISRCTN 81117481]. *J Pain Symptom Manage* 2013; 45: 488–505.
13. Schag CC, Heinrich RL and Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. *J Clin Oncol* 1984; 2: 187–193.
14. Amano K, Maeda I, Morita T, et al. C-reactive protein, symptoms and activity of daily living in patients with advanced cancer receiving palliative care. *J Cachexia Sarcopenia Muscle* 2017; 8: 457–465.
15. Hjermstad MJ, Aass N, Aielli F, et al. Characteristics of the case mix, organisation and delivery in cancer palliative care: a challenge for good-quality research. *BMJ Support Palliat Care*. Epub ahead of print 31 May 2016. DOI: 10.1136/bmjspcare-2015-000997.
16. Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. *Eur J Cancer* 2006; 42: 55–64.
17. Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. *BMJ* 1990; 300: 230–235.
18. Laird BJ, Scott AC, Colvin LA, et al. Cancer pain and its relationship to systemic inflammation: an exploratory study. *Pain* 2011; 152: 460–463.
19. Al-Mazidi S, Farhat K, Nedjadi T, et al. Association of interleukin-6 and other cytokines with self-reported pain in prostate cancer patients receiving chemotherapy. *Pain Med* 2018; 19: 1058–1066.
20. Loumaye A and Thissen JP. Biomarkers of cancer cachexia. *Clin Biochem* 2017; 50: 1281–1288.
21. Vazeille C, Jouinot A, Durand JP, et al. Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy. *Am J Clin Nutr* 2017; 105: 1139–1147.
22. Gould DW, Lahart I, Carmichael AR, et al. Cancer cachexia prevention via physical exercise: molecular mechanisms. *J Cachexia Sarcopenia Muscle* 2013; 4: 111–124.
23. Parmar MP, Vanderbily BL, Kanbalian M, et al. A multidisciplinary rehabilitation programme for cancer cachexia improves quality of life. *BMJ Support Palliat Care* 2017; 7: 441–449.